It was concluded by the EU’s executive arm that the acquisition would not have a negative impact on competition in Europe. They stated, “The Commission’s examination has shown that the proposed transaction would not lead to significant combined market shares in the product categories where the parties’ activities overlap.
“In addition, the proposed transaction also does not raise concerns in the treatment of multiple sclerosis, where both parties are developing treatments. In all cases there will remain a sufficient number of other credible competitors.”
Are you looking for a new position in the EU? Click here to search our current pharmaceutical jobs online now.